Not yet medically reviewed, information on this site is in preparation and has not been verified by a medical reviewer.
Legality · 2-FDCK

Is 2-FDCK legal in South Africa?

Confirmed against a primary sourceVerified October 4, 2026
Legal status
Controlled as a Schedule 7 substance under the Medicines and Related Substances Act 101 of 1965, as at the SAHPRA consolidation of 1 August 2025; it is not printed in the Drugs and Drug Trafficking Act 140 of 1992.
Consequences if caught
Schedule 7 prints it on page 195 as "2-Fluorodeschloroketamine." So the fluorinated analogue is in Schedule 7 while ketamine itself is a Schedule 5 medicine. Section 22A (9) (a) (i) of the Medicines Act says no person shall "acquire, use, possess, manufacture or supply any Schedule 7 or Schedule 8 substance" unless the Director-General has issued a permit for it, and its proviso lets the Director-General authorise use only to provide a medical practitioner, analyst, researcher or veterinarian with the substance for a particular patient or for education, analysis or research. Section 29 (k) makes it an offence to contravene "any provision of section 22A", and section 30 (1) makes a person convicted of an offence referred to in section 29 "liable to a fine, or to imprisonment for a period not exceeding 10 years." Section 30 (2) lets the court declare the substance forfeited to the State, and section 30 (4) makes a magistrate's court competent to impose the penalty. Section 22A (11) (a) also forbids importing or exporting any Schedule 7 substance without a permit, and (11) (b) says such a permit "may be issued for any purpose other than the satisfaction or relief of a habit or craving". Under the Drugs Act the position is different. The starting point for this family in most jurisdictions is a ketamine entry, and this Act has none: the string ketamine occurs zero times in the whole 84,091 byte text. What Part III does carry is a closed list of arylcyclohexylamines, printed as "Phencyclidine and the congeners thereof, namely, N-ethyl-1-phenylcyclohexylamine (PCE), 1-(1-phenylcyclohexyl) pyrrolidine (PHP or PCPY) and 1-[1-(2-thienyl) cyclohexyl] piperidine (TCP)." The entry names three congeners and this substance is not one of them, and the schedule chose to name rather than to describe a class. So the question becomes whether a fluorinated analogue of a substance that is itself unlisted is a homologue of the three that are listed. The Drugs Act limb that could still reach it is Part III paragraph 2 (e), "(e) all homologues of the listed substances (being any chemically related substances that incorporate a structural fragment into their structures that is similar to the structure of a listed substance or exhibit pharmacodynamic properties similar to the listed substances in this Part of the Schedule), unless listed separately in any Part of Schedule 2." The equivalent limb in Part I is paragraph 2 (c). If it does reach the substance, use or possession falls under section 4 (b), an offence under section 13 (d) punishable under section 17 (d) by such fine as the court may deem fit, imprisonment for a period not exceeding 15 years, or both, and dealing falls under section 5 (b), an offence under section 13 (f) punishable under section 17 (e) by imprisonment for a period not exceeding 25 years, or that imprisonment and a fine. If it does not, the Drugs Act does not reach the substance at all. The Act supplies no test for deciding a homologue case. Capital exposure: none, and life exposure: none. Section 30 (1) of the Medicines Act fixes the penalty for an offence under section 29 at a fine or imprisonment for a period not exceeding 10 years, and section 17 sets out the whole penalty scale of the Drugs Act, whose highest figure is 25 years for dealing; neither Act carries a death sentence or a sentence of life imprisonment.
If prescribed or medical
There is no prescription route. Section 22A (9) (a) (i) says no person shall "acquire, use, possess, manufacture or supply any Schedule 7 or Schedule 8 substance" unless the Director-General has issued a permit for it, and its proviso lets the Director-General authorise use only to provide a medical practitioner, analyst, researcher or veterinarian with the substance for a particular patient or for education, analysis or research. The Drugs Act's own exceptions in section 4, paragraphs (i) to (vi), run through a practitioner acting in accordance with the Medicines Act, and section 2 of the Drugs Act says it applies "in addition to, and not in substitution for" the Medicines Act.
Documentation
Medicines Act search record, 3 October 2026. Terms searched: fluorodeschloroketamine, 2-FDCK, deschloroketamine and ketamine. The systematic name returns one Schedule 7 entry; 2-FDCK returns nothing because the entry does not print the short name. The consolidation is a text PDF of 199 pages and was searched as extracted text, every schedule from 0 to 8. The Medicines Act schedules are stated as at the SAHPRA Consolidated Schedules of 1 August 2025, which on a comparison of two of its changes, the inserted fluconazole entry in Schedule 2 and the reworded nicotine metered spray line, both read on pages 4 and 6 of the scanned notice, already carry Government Notice R6466 of 1 August 2025; the rest of that notice was not read. That consolidation is read with Government Notice 7446 in Government Gazette 54627 of 8 May 2026, whose only change is to insert a veterinary yohimbine entry in Schedule 4; both were read on 3 October 2026. SAHPRA now labels the 1 August 2025 file an archived version and offers its July 2026 consolidation only through a Microsoft sign in that refused an anonymous request, so that file was not read, and this does not rule out a later amendment. The text of the Medicines Act read is the consolidation published in Government Gazette 40869 of 26 May 2017, whose list of amending Acts ends at Act 14 of 2015; a search on 3 October 2026 found no later amending Act, which does not rule one out. Drugs Act search record carried from the earlier cell. Search record. The terms searched were 2-fdck, 2-FDCK, fluorodeschloroketamine, ketamine and arylcyclohexylamine. All return zero occurrences. The text read for this cell is the Juta consolidation of the Act downloaded on 29 May 2025, taken from the Department of Justice copy at justice.gov.za whose sha256 begins bc1216a3. It carries the substitution of Schedules 1 and 2 by section 2 of Act 14 of 2022 with effect from 14 December 2022, and it marks section 7 of the Cannabis for Private Purposes Act 7 of 2024, the provision that would amend Schedule 2 again, as not yet put into operation by proclamation. The schedules are stated as at that consolidation and this does not rule out a later amendment made or commenced since.
Primary sources
  • Medicines and Related Substances Act 101 of 1965, Schedules made under section 22A (2), Schedule 7, page 195
  • SAHPRA Consolidated Schedules of 1 August 2025, read on 3 October 2026
  • sahpra.org.za
  • Government Notice 7446, Government Gazette 54627 of 8 May 2026, read on 3 October 2026
  • gov.za
  • Medicines and Related Substances Act 101 of 1965, ss 1, 22A, 29 and 30, consolidation in Government Gazette 40869 of 26 May 2017, read on 3 October 2026
  • sahpra.org.za
  • Drugs and Drug Trafficking Act 140 of 1992 fetched again on 3 October 2026, sha256 beginning bc1216a3 and byte identical to the cached copy
  • Drugs and Drug Trafficking Act 140 of 1992, Schedule 2 open homologue limb, closed congener list read and rejected
  • Drugs and Drug Trafficking Act 140 of 1992, ss 1, 2, 3, 4, 5, 13, 17 and 19, with Schedules 1 and 2
  • justice.gov.za
  • read from the cached text at research/instruments/south-africa/za-drugs-act-140-1992.txt, 84,091 bytes, against the.pdf beside it at 127,460 bytes
  • the consolidation is dated 29 May 2025 and carries the Act 14 of 2022 substitution of both schedules with effect from 14 December 2022

Court records

We have not yet assessed whether court records are publicly available for this jurisdiction.

Other substances confirmed in South Africa